Search clinical trials for: Myfortic®

Total 13777 results

Novartis Pharmaceuticals

Terminated

Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

Kidney Transplantation

Italy
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
University of California, San Francisco

Withdrawn

(-)-Epicatechin and Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Novartis Pharmaceuticals

Completed

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients (EVITA)

Renal Transplant

Spain
Klemens Budde
Novartis Pharmaceuticals

Completed

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

Immunosuppression | Transplantation | Drug Interaction

Germany
Poitiers University Hospital

Completed

Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

Chronic Kidney Disease

France
Novartis Pharmaceuticals

Completed

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (SIMCER)

Liver Transplantation

France
Novartis Pharmaceuticals

Terminated

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

Renal Transplantation

United States
University of North Carolina, Chapel Hill
Novartis Pharmaceuticals

Completed

Myfortic Conversion Trial in OLT Recipients With GI Intolerance

GI Disturbance

United States
Medical College of Wisconsin

Withdrawn

Myfortic in High MELD Liver Transplantation

High Model for End-Stage Liver Disease (MELD) Score

United States
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

No longer available

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

Diabetes Mellitus, Type 1

United States
Ain Shams University

Completed

Mineralocorticoid Use in COVID-19 Patients

COVID-19 | ARDS

Egypt
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study) (IDEALE)

Renal Transplantation

France
Novartis Pharmaceuticals

Completed

Everolimus in de Novo Kidney Transplant Recipients (NEVERWOUND)

Kidney Transplantation

Italy
Takeda

No longer available

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Malaria
Erasmus Medical Center
Novartis Pharmaceuticals

Terminated

Myfortic Versus Azathioprine in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Netherlands
National Institute of Allergy and Infectious Diseases...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Clinical...

Completed

Extended Follow-Up After Islet Transplantation in T1D

Type 1 Diabetes (T1D) | Islet Transplantation

United States
Lorenzo Gallon
Bristol-Myers Squibb

Completed

Belatacept 3 Month Post Transplant Conversion Study

EBV | Transplant; Failure, Kidney

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

International Multicenter Mycotic Aneurysm Aorto-iliac Study (MAAI)

Aortic Diseases | Mycotic Aneurysm

Italy
Asan Medical Center
Samsung Medical Center; Seoul National University Hospital

Completed

Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients (OPTIMUM)

Kidney Transplantation

Korea, Republic of
Massachusetts General Hospital

Terminated

Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis

Chronic Pancreatitis

United States
University of Saskatchewan

Withdrawn

Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring (COBACAM)

Cardiovascular Disease | Kidney Transplantation | Kidney Transplant Recipients | Cardiovascular Outcomes

Canada
Zachariah Michael DeFilipp
Regimmune Corporation

Active, not recruiting

Haplo Peripheral Blood Sct In GVHD Prevention

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | AML | Non Hodgkin Lymphoma | MDS | Myeloproliferative Disorder | GVHD | Graft Vs Host Disease | ALL | CMML | Blood Stem Cell Transplant Failure | MPN | Chemosensitive Hodgkin Lymphoma

United States
Washington University School of Medicine

Withdrawn

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Multiple Myeloma | Myeloma-Multiple
Novartis Pharmaceuticals

Completed

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients (CERTITEM)

Renal Interstitial Fibrosis

France
Hospital Universitário São José

Unknown

Efficacy of Certican® in Combination With Myfortic® in Renal (HUSJ1)

Disorder Related to Renal Transplantation

Brazil
Novartis Pharmaceuticals

Completed

RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency

Liver Transplantation

Switzerland, Germany
Assistance Publique - Hôpitaux de Paris
Novartis

Completed

Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome (MSN)

Nephrotic Syndrome

France
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Renal Transplantation

United States
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Clinical Trials in Organ Transplantation

Completed

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Kidney Transplant Recipients | Living-Donor Kidney Transplant

United States
University of Florida
Novartis

Completed

Desensitization of Renal Transplant Candidates

End Stage Renal Disease | Kidney Transplantation

United States
McGill University Health Centre/Research Institute...
Novartis

Unknown

Myfortic in Heart Transplant Patients With Gastrointestinal (GI) Symptoms

Heart Transplant Patients

Canada
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)

Active, not recruiting

Tolerance by Engaging Antigen During Cellular Homeostasis (TEACH)

Kidney Transplantation | Renal Transplantation | Renal Transplant Recipient

United States
Rennes University Hospital

Terminated

Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression (AFLUCO2)

Renin Angiotensin

France
Genovate Biotechnology Co., Ltd.,
Novartis

Unknown

Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study

Uveitis

Taiwan
Milton S. Hershey Medical Center
Novartis Pharmaceuticals

Completed

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

Renal Failure | Immunosuppression

United States
Novartis Pharmaceuticals

Completed

SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus

Renal Transplanted Recipients

Australia
Cedars-Sinai Medical Center
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Heart Transplantation | Gastrointestinal Symptoms

United States
University of Cincinnati
Novartis Pharmaceuticals

Completed

Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

Kidney Transplant Recipients

United States
Foothills Medical Centre
Novartis

Unknown

Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)

Kidney Transplant

Canada
Rodolfo Alejandro

Recruiting

Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

Type 1 Diabetes Mellitus

United States
University of Pittsburgh
Novartis Pharmaceuticals

Completed

A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients

Immunosuppression

United States
Novartis Pharmaceuticals

Active, not recruiting

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Lupus Nephritis

Taiwan
University of Pittsburgh
Novartis Pharmaceuticals

Completed

Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

Immunosuppression

United States
National Institute of Allergy and Infectious Diseases...
PPD

Active, not recruiting

Tocilizumab in Cardiac Transplantation

Heart Transplant

United States
Chong Kun Dang Pharmaceutical

Completed

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

Healthy

Korea, Republic of
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

Autoimmune Disease

Germany
University Hospital Muenster
Novartis

Completed

Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome

Primary Sjogren's Syndrome

Germany
Galderma R&D

Completed

Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis

Atopic Dermatitis

Philippines, China

Search clinical trials for: Myfortic®

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations